300 related articles for article (PubMed ID: 7877106)
1. Candida albicans, the opportunist. A cellular and molecular perspective.
Dupont PF
J Am Podiatr Med Assoc; 1995 Feb; 85(2):104-15. PubMed ID: 7877106
[TBL] [Abstract][Full Text] [Related]
2. Looking into Candida albicans infection, host response, and antifungal strategies.
Wang Y
Virulence; 2015; 6(4):307-8. PubMed ID: 25590793
[TBL] [Abstract][Full Text] [Related]
3. Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders.
Cassone A; Cauda R
AIDS; 2012 Jul; 26(12):1457-72. PubMed ID: 22472853
[TBL] [Abstract][Full Text] [Related]
4. Dissecting Candida albicans Infection from the Perspective of C. albicans Virulence and Omics Approaches on Host-Pathogen Interaction: A Review.
Chin VK; Lee TY; Rusliza B; Chong PP
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763544
[No Abstract] [Full Text] [Related]
5. Disruption of the intestinal mucosal barrier in Candida albicans infections.
Yan L; Yang C; Tang J
Microbiol Res; 2013 Aug; 168(7):389-95. PubMed ID: 23545353
[TBL] [Abstract][Full Text] [Related]
6. Candida albicans pathogenicity: a proteomic perspective.
Niimi M; Cannon RD; Monk BC
Electrophoresis; 1999 Aug; 20(11):2299-308. PubMed ID: 10493133
[TBL] [Abstract][Full Text] [Related]
7. Proteomic profiling of serologic response to Candida albicans during host-commensal and host-pathogen interactions.
Pitarch A; Nombela C; Gil C
Methods Mol Biol; 2009; 470():369-411. PubMed ID: 19089396
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidiasis: the cell wall as a potential molecular target for antifungal therapy.
Gozalbo D; Roig P; Villamón E; Gil ML
Curr Drug Targets Infect Disord; 2004 Jun; 4(2):117-35. PubMed ID: 15180460
[TBL] [Abstract][Full Text] [Related]
9. Adherence mechanisms of Candida albicans.
Cotter G; Kavanagh K
Br J Biomed Sci; 2000; 57(3):241-9. PubMed ID: 11050778
[TBL] [Abstract][Full Text] [Related]
10. Adaptive immune responses to Candida albicans infection.
Richardson JP; Moyes DL
Virulence; 2015; 6(4):327-37. PubMed ID: 25607781
[TBL] [Abstract][Full Text] [Related]
11. Oral Candida: clearance, colonization, or candidiasis?
Cannon RD; Holmes AR; Mason AB; Monk BC
J Dent Res; 1995 May; 74(5):1152-61. PubMed ID: 7790592
[TBL] [Abstract][Full Text] [Related]
12. Interactions of the fungal pathogen Candida albicans with the host.
Rupp S
Future Microbiol; 2007 Apr; 2(2):141-51. PubMed ID: 17661651
[TBL] [Abstract][Full Text] [Related]
13. Candida albicans - Biology, molecular characterization, pathogenicity, and advances in diagnosis and control - An update.
Dadar M; Tiwari R; Karthik K; Chakraborty S; Shahali Y; Dhama K
Microb Pathog; 2018 Apr; 117():128-138. PubMed ID: 29454824
[TBL] [Abstract][Full Text] [Related]
14. Candida and human disease.
Palma-Carlos AG; Palma-Carlos ML
Eur Ann Allergy Clin Immunol; 2004 Oct; 36(8):291-6. PubMed ID: 15623242
[TBL] [Abstract][Full Text] [Related]
15. Human fungal pathogen Candida albicans in the postgenomic era: an overview.
Kabir MA; Hussain MA
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):121-34. PubMed ID: 19622061
[TBL] [Abstract][Full Text] [Related]
16. [Virulence factors of Candida albicans].
Staniszewska M; Bondaryk M; Piłat J; Siennicka K; Magda U; Kurzatkowski W
Przegl Epidemiol; 2012; 66(4):629-33. PubMed ID: 23484392
[TBL] [Abstract][Full Text] [Related]
17. Modulating Host Signaling Pathways to Promote Resistance to Infection by
Carpino N; Naseem S; Frank DM; Konopka JB
Front Cell Infect Microbiol; 2017; 7():481. PubMed ID: 29201860
[No Abstract] [Full Text] [Related]
18. [Candidiasis: molecular basis of parasitic adaptation of opportunistic pathogenic protists].
Poulain D
Ann Parasitol Hum Comp; 1990; 65 Suppl 1():125-30. PubMed ID: 2264674
[TBL] [Abstract][Full Text] [Related]
19. Effects of IgY against Candida albicans and Candida spp. Adherence and Biofilm Formation.
Fujibayashi T; Nakamura M; Tominaga A; Satoh N; Kawarai T; Narisawa N; Shinozuka O; Watanabe H; Yamazaki T; Senpuku H
Jpn J Infect Dis; 2009 Sep; 62(5):337-42. PubMed ID: 19762981
[TBL] [Abstract][Full Text] [Related]
20. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans.
Santos AL; Braga-Silva LA
Mini Rev Med Chem; 2013 Jan; 13(1):155-62. PubMed ID: 23256485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
